JSCO2016: International Session 1 Lung Cancer

TOP > Annual Meeting > Abstract archives > 2016 Abstracts > JSCO2016: International Session 1 Lung Cancer

The 54th Annual Meeting of Japan Society of Clinical Oncology (JSCO2016)

"Renovation of Cancer Medicine in the Mature Society"



International Session 1: Lung Cancer
International Session 2: Colorectal Cancer
International Session 3: Gastric Cancer
International Session 4: Urological Cancer (Prostate and Renal Cancer)
International Session 5: Supportive Care for Adverse Events
International Session 6: Gynecological Cancer (Uterine Body Cancer and Ovarian Cancer)
International Session 7: Central Nervous System Tumor
International Session 8: New Development of Particle Beam Therapy for Cancer
International Session 9: International Cooperation in Radiation Medicine
International Session 10: Recent Advances In Cancer Immunotherapy
International Session 11: Breast Cancer
International Session 12: Pharmacology of Antitumor Agents: New Drug Application (NDA)
International Session 13: Malignant Lymphoma
International Session 14: Palliative Care
International Session 15: Radiation Therapy
International Session 16: Head and Neck Cancer
International Session 17: Skin Cancer (Malignant Melanoma)
International Session 18: Hepato-Biliary and Pancreas Cancers
International Session 19: Leukemia
International Session 20: Ethics for Clinical Research
International Session 21: Esophageal Cancer
International Session 22: Bone and Soft Tissue Tumor
FACO/JSCO Joint Symposium

Abstract Archives (in Japanese)



International Session 1: Lung Cancer


Treatment guideline in Japan
Nobuyuki Yamamoto (Division of Pulmonary Medicine & Medical Oncology, Wakayama Medical University Hospital)
The Japan Lung Cancer Society has updated its guidelines annually since 2010. The update procedure begins with a comprehensive literature search by experts, followed by critical appraisal and appropriate review by responsible personnel. The updates are then determined through consultation among all the board members, including medical oncologists, radiation oncologists, surgeons, and statisticians. Here, we report an English version of the Japan Lung Cancer Society Guidelines for Advanced Non-Small-Cell Lung Cancer (NSCLC) (stages IV) 2015.
The first-line chemotherapy is determined on the basis of 4 clinical features: histological type (squamous cell carcinoma or not), presence of EGFR/anaplastic lymphoma kinase (ALK) gene mutation, PS, and age (75 years or older, or less than 75). In the case of non-squamous cell carcinoma, identification of EGFR/ALK status is recommended for all cases.
Several key drugs such as 3rd-Generation EGFR-TKI, 2nd-Generation AKL-TKI, ramucirumab and PD-1 inhibitors were approves in Japan whithin a year, Thus, we updated the gusideline 2015 to version 1.1.


Year in review from Europe
Rolf A. Stahel (University Hospital Zürich, Switzerland)
Not received


Year in review from Asia
Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China)
In last year there have been considerable advances in the treatments patients with non-small cell lung cancer (NSCLC). Asia make a great contribution in globe drugs development and treatment strategies. In new lung cancer TNM staging 79% cases was contributed from Asia including Japan, Korea and China. For early stage resectable NSCLC a RCT (CSLC0501) from China comparing adjuvant with neo-adjuvant chemotherapy in stage 1-3 resected NSCLC was reported on ESMO 2016. The results showed that no statistically significant difference between two arms but a trend in favour of adjuvant treatment in DFS and OS in 5 years. From two RCTs Asia experts reported liquid biopsy in dynamic monitor EGFR mutation for predicting survival of EGFR mutant patients. The results extended clinical use of ctDNA test and potentially make much precision in NSCLC treatment. Majority of lung cancer with EGFE/ALK and other rare mutation make Asia physicians crucial in biomarker driven clinical trials. J-ALEX trial conducted by Japanese first time showed alectinib superior to crizotinib in 1st line setting. ROS1 trials lead by China, Japan was the largest trial global and confirmed the clinical meaningful of anti ROS1 therapy. China developed a trial design in combination EGFRi with cMETi for overcoming EGFR TKIs resistant. The preliminary results in phase 1/2 trial was promising. The RR was 50% in cMET amplification patients. In brain and leptomeningeal metastasis PIs from Taiwan and Korea conducted BLOOM studies and showed that osimertinib and AZD3759 had excellent efficacy in this setting. The experts from Asia now play a very important role in lung cancer research in global.

Ramon, et al. J Thorac Oncol 2015;10:990
Wu, et al. ESMO 2016:3823
Mok, et al. Clin Cancer Reser 2015;21:3196
Zhou, et al. J Hem Oncol 2016;9:1
Nakihara et al. ASCO 2016:9008
Gota, et al. ASCO 2016:9022
Wu, et al. ASCO 2016:9020


Past Annual Meetings

 [go to the top of this window]